Walking Fish Therapeutics, a leader in B cell engineering, announced the close of $50M Series A financing led by investors including Emerson Collective, Illumina Ventures and Quan Capital.

Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells' capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.